Oill P A, Kalmanson G M, Guze L B
Antimicrob Agents Chemother. 1981 Oct;20(4):491-2. doi: 10.1128/AAC.20.4.491.
The activities of ampicillin, rifampin, streptomycin, and their combinations were evaluated in vitro against Streptococcus faecalis strain GK and in vivo in rats with an established pyelonephritis resulting from challenge with this same enterococcus. In vitro synergy was demonstrated between all combinations. Comparison of the log colony-forming units of S. faecalis recovered per gram of kidney tissue showed that all treated groups had significant lower numbers than controls (P less than 0.001). Ampicillin plus streptomycin or ampicillin alone was superior to rifampin alone or rifampin plus streptomycin at each interval (P less than 0.001). There was no significant difference between ampicillin and rifampin plus ampicillin. The disparity between in vitro and in vivo results again raises some doubts as to the relevance of in vitro observations to clinical outcome.
对氨苄西林、利福平、链霉素及其组合针对粪肠球菌GK菌株进行了体外活性评估，并在因该肠球菌攻击而导致肾盂肾炎的大鼠体内进行了评估。所有组合均显示出体外协同作用。比较每克肾组织中回收的粪肠球菌的对数集落形成单位，结果表明所有治疗组的数量均显著低于对照组（P小于0.001）。在每个时间间隔，氨苄西林加链霉素或单独使用氨苄西林均优于单独使用利福平或利福平加链霉素（P小于0.001）。氨苄西林与利福平加氨苄西林之间无显著差异。体外和体内结果之间的差异再次引发了对体外观察结果与临床结局相关性的一些质疑。
